News about Insulet

Insulet Corporation Achieves Key FDA Clearance and Opens New Malaysian Facility Amid Strong Financial Growth,...
Aug 27 2024
Insulet Corporation (NASDAQ: PODD), a pioneer in tubeless insulin pump technology, has reached significant milestones that enhance its position in the...

Omnipod 5 Revamping Diabetes Management with Groundbreaking FDA Clearance and Stellar Financial Growth
Aug 26 2024
In a landmark moment for diabetes management, Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has announced t...

Insulet Unveils Ambitious Manufacturing Hub in Malaysia to Transform Diabetes Care,
Aug 14 2024
*Insulet Opens New Manufacturing Facility in Malaysia, Expanding Reach of Innovative Diabetes Care Solutions*In a significant stride toward enhancing ...

Insulets Strong Growth and Pivotal Innovations Position Company at Forefront of Diabetes Care
Aug 08 2024
Insulet Corporation, a leader in tubeless insulin pump technology, has shared its impressive financial and clinical performance for the second quarter...

Assessing the Underperformance of Insulet Corporation Shares in the Market Rally
Jul 09 2024
In recent weeks, Insulet Corporation*s stock performance has been trailing behind the overall market. This article aims to interpret various articles ...

Insulet Corporation A Rising Force in the Diabetes Market
Jul 02 2024
In recent news, Insulet Corporation (PODD) has emerged as a leading player in the healthcare sector, particularly in the diabetes space. This article ...

Insulets Omnipod Enhances Type 2 Diabetes Treatment, Paving the Way for Enhanced Healthcare Solutions ...
Jun 26 2024
Insulet, the pioneering insulin pump manufacturer, made waves at a recent conference by showcasing the transformative impact of its automated insulin ...

Omnipod 5 Bolsters Type 2 Diabetes Care with Enhanced Outcomes and Quality of Life,
Jun 24 2024
Omnipod 5: A Revolution in Type 2 Diabetes Management Demonstrates Promising Clinical Outcomes and Improved Quality of Life*ACTON, Mass.* -- Insulet ...

Pioneering Diabetes Care Insulet?s Omnipod 5 Sets New Standards with Breakthrough Trial Results and Glo...
Jun 23 2024
**In a transformative stride for diabetes management, Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has p...

Omnipod 5 Pivotal Trial Demonstrates Groundbreaking Benefits in Type 2 Diabetes Care
Jun 22 2024
Insulets SECURE-T2D Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 DiabetesACTON, Mass. - Insule...

Catchy Headline: Insulet Corporation Soars to New Heights with Impressive Growth in Recent Fiscal Period
May 11 2024
Insulet Corporation, the global leader in tubeless insulin pump technology, recently released its financial results for the most recent fisc...

Insulet Corporation Reports Record-Breaking Financial Performance in Fourth Quarter of 2023
Feb 23 2024
Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has reported impressive financial results for the period of O...

Insulet Corporation Surges Ahead with Record-breaking Revenue Rise, Reaching Profitability Milestone in Q3 2023
Nov 04 2023
Insulet Corporation Reports Strong Revenue Rise and Turns Profitable in Q3 2023ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global lead...

Astonishing Second Quarter Rebound: Insulet Corporation*s EPS Soars to $0.39, Defying Stock*s Recent Dip
Aug 11 2023
During the past 5 trading days, shares of Insulet Corporation experienced a significant decrease, dropping by -13.64%. This decline compounds the comp...

Insulet Corporation Reports Significant ROA Improvement in Q1 2023, Despite Minor Decline in EPS
May 06 2023
Insulet Corporation, a medical device company headquartered in Massachusetts, has reported a positive return on asset (ROA) of 0.03% in its first quar...